[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502935":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":33,"locations":41,"responsibleParty":59,"collaborators":12,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":12,"enrollmentInfo":72,"targetDuration":12,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":44,"whyStopped":12,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Guideline-directed medical treatment group","NO_INTERVENTION","In the GDMT group, medical treatment for patients with left ventricular dysfunction will be performed under current ACC\u002FAHA\u002FSCAI or ESC\u002FEACTS guidelines for heart failure.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Revascularization group","EXPERIMENTAL","In the revascularization group, patients will undergo percutaneous coronary intervention (PCI) using standard techniques under current ACC\u002FAHA\u002FSCAI or ESC\u002FEACTS guidelines. In the revascularization group, the procedure must be within 2 weeks of randomization.\n\nRevascularization criteria is presented as below. Revascularization indication\n\n1. Diameter stenosis \\>90% by visual assessment\n2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)\n3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.\n\n   * Left main artery\n   * Proximal to mid left anterior descending artery\n   * Proximal left circumflex artery in left dominant coronary arterial system\n   * Proximal to distal right coronary artery in right dominant coronary arterial system",[18],"Procedure: Percutaneous coronary intervention",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"PROCEDURE","Percutaneous coronary intervention","Revascularization indication\n\n1. Diameter stenosis \\>90% by visual assessment\n2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)\n3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.\n\n   * Left main artery\n   * Proximal to mid left anterior descending artery\n   * Proximal left circumflex artery in left dominant coronary arterial system\n   * Proximal to distal right coronary artery in right dominant coronary arterial system",[14],[26,29,31],{"name":27,"affiliation":5,"role":28},"Young Bin Song, MD, PhD","STUDY_CHAIR",{"name":27,"affiliation":5,"role":30},"PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":5,"role":30},"Joo Myung Lee, MD, MPH, PhD",[34,38],{"name":27,"role":35,"phone":36,"phoneExt":12,"email":37},"CONTACT","82-2-3410-6653","youngbien.song@samsung.com",{"name":32,"role":35,"phone":39,"phoneExt":12,"email":40},"82-2-3410-3419","drone80@hanmail.net",[42],{"facility":43,"status":44,"city":45,"state":12,"zip":46,"country":47,"countryCode":12,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Samsune Medical Center","RECRUITING","Seoul","06351","South Korea",{"type":49,"coordinates":50},"Point",[51,52],126.9784,37.566,{"lat":52,"lon":51},[55,58],{"name":27,"role":35,"phone":56,"phoneExt":12,"email":57},"0234102575","youngbin.song@gmail.com",{"name":32,"role":35,"phone":56,"phoneExt":12,"email":40},{"type":30,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Young Bin Song","Professor","100502935","revascularization-versus-medical-treatment-in-patients-with-ischemic-left-ventricular-dysfunction-100502935",false,"NCT05828719","Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction","Randomized Controlled Trial of Revascularization Versus Medical Treatment on Clinical Outcomes in Patients With Reduced Left Ventricular Function","RESTORE-PCI","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Patients with stage C heart failure and left ventricular ejection fraction\\\u003C40%\n* Patients with significant coronary artery stenosis (diameter stenosis\\>50% with proven inducible myocardial ischemia by invasive physiologic assessment)\n* Coronary artery disease is amenable for percutaneous coronary intervention (PCI)\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive approach and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Myocardial infarction by universal definition within 4 weeks of randomization\n* Non-viable myocardium in myocardial viability test (cardiac magnetic resonance, dobutamine-stress echocardiography, delayed single-photon emission computerized tomography, or aneurysmal change in echocardiography)\n* Target lesions not amenable for PCI by operators' decision\n* Patients who need left ventricular assisted device (LVAD) or heart transplantation at the time of randomization\n* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus\n* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)\n* Pregnancy or breast feeding\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Unwillingness or inability to comply with the procedures described in this protocol.","ALL","19 Years",{"count":73,"type":74},900,"ESTIMATED","INTERVENTIONAL",[77],"NA","Randomized trial to compare clinical outcomes between revascularization versus medical treatment alone in patients with ischemic cardiomyopathy and left ventricular dysfunction.",[80,81],"Heart Failure With Reduced Ejection Fraction","Ischemic Cardiomyopathy",[83,84,85,86],"ischemic cardiomyopathy","percutaneous coronary intervention","ejection fraction","guideline-directed medical treatment","2025-03-12",{"date":89,"type":90},"2025-03-14","ACTUAL",{"date":92,"type":90},"2023-06-16",{"date":94,"type":74},"2030-12-31",{"name":5,"class":6},1]